ESTRO 2024 - Abstract Book

S97 ESTRO 2024 Figure 1 Overview of the early stage researchers and their projects (top row) as well as their supervisors (bottom row) involved in the RAPTOR work package ”Verification” Invited Speaker

3485

Rare tumours treated with radiotherapy: Specific or standardised care

Gwendoline Jacquin

Institut Gustave Roussy, Radiotherapy, Villejuif, France

Abstract:

Radiotherapy, whether for curative or palliative purposes, has demonstrated efficacy across diverse cancer types. The criterion of patient immobilization plays a pivotal role in delivering effective radiation therapy. Recent technological advancements have significantly enhanced precision, expectations, and reliability. This symposium focuses on immobilization devices in radiotherapy for rare cancers. Gwendoline's exhaustive review spans studies from 2000 to 2024, incorporating insights from colleagues, a Europe-wide survey, and her own expertise. The symposium aims to delineate the optimal approach to immobilization devices for rare cancers. The exploration navigates the choice between standardized and organ-specific devices, illustrating examples that underscore potential benefits or limitations in specific cases. This comprehensive overview contributes valuable perspectives to the evolving landscape of radiotherapy for rare cancers.

3486

Rationale of dose de-escalation for stage 3 NSCLC

Corinne Faivre-Finn

the Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom. University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom

Abstract:

Stage 3 Non-Small Cell Lung Cancer (NSCLC) poses significant challenges in achieving optimal therapeutic outcomes, especially with the historical setbacks of failed dose-intensification trials, such as RTOG0617 and PET-boost. I will delve into the rationale for dose de-escalation in the era of immunotherapy, focusing on critical aspects relating to toxicity. I will discuss the reasons behind the unfavorable outcomes of dose-intensification trials, emphasizing the necessity to de-escalate the dose to specific sub-structures. In particular, the adverse effects on the heart, immune system, and central airways underscore the need for a paradigm shift in treatment approaches.

The discussion will then transition to the current standard of care for dose and fractionation in 2024, taking into account the integration of immunotherapy in the stage 3 setting. Insights into how radiation treatment can be de-